Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages “There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns

OMB proposal to sideline peer review sparks widespread opposition
Nearly 500,000 public comments flood in—here are some highlights

The Trump administration’s effort to give political appointees greater authority over federally-funded science is colliding with fierce objections from researchers, universities, medical organizations, and members of Congress.

July 17, 2026

Vol.52 No.28

By Claire Marie Porter

Cancer Policy

White House regulatory priorities include “aggressive” HHS agenda

The White House Office for Regulatory Affairs and Information released a series of documents detailing each agency’s regulatory priorities for the coming year.

OMB’s plan to increase political control of science faces stiff opposition on Capitol Hill

The Trump administration has a fight on its hands as it pushes forward with a plan to exert greater political control over government funding of science.

AACR urges OMB to retract proposed rule on federally funded research

The American Association for Cancer Research is urging the White House Office of Management and Budget to rescind its recent proposed rule that would give the administration unprecedented political control over government-funded science.

OMB draft rule politicizing research should be rescinded, House Dems urge in a letter to Bhattacharya

Democratic leaders of the House Committee on Energy and Commerce are urging NIH Director Jay Bhattacharya to voice objections to a proposed rule from the Office of Management and Budget that would give the administration unprecedented political control over government-funded science.

Is psilocybin heading to a cancer clinic near you?
Reversing Nixon-era taboo, Trump orders FDA to fast-track psychedelics and ARPA-H to fund research

Earlier this year, Joe Rogan, host of “The Joe Rogan Experience” podcast, sent a text to President Donald Trump.

June 18, 2026

Vol.52 No.24

By Sara Willa Ernst

Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages

“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns

YOU MAY BE INTERESTED IN

OMB proposal to sideline peer review sparks widespread opposition
Nearly 500,000 public comments flood in—here are some highlights

White House regulatory priorities include “aggressive” HHS agenda

OMB’s plan to increase political control of science faces stiff opposition on Capitol Hill

AACR urges OMB to retract proposed rule on federally funded research

OMB draft rule politicizing research should be rescinded, House Dems urge in a letter to Bhattacharya

Is psilocybin heading to a cancer clinic near you?
Reversing Nixon-era taboo, Trump orders FDA to fast-track psychedelics and ARPA-H to fund research

Renew today!

Subscriber content

Never miss an issue!

Login

Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages

“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns

YOU MAY BE INTERESTED IN

OMB proposal to sideline peer review sparks widespread oppositionNearly 500,000 public comments flood in—here are some highlights

White House regulatory priorities include “aggressive” HHS agenda

OMB’s plan to increase political control of science faces stiff opposition on Capitol Hill

AACR urges OMB to retract proposed rule on federally funded research

OMB draft rule politicizing research should be rescinded, House Dems urge in a letter to Bhattacharya

Is psilocybin heading to a cancer clinic near you?Reversing Nixon-era taboo, Trump orders FDA to fast-track psychedelics and ARPA-H to fund research

Never miss an issue!

Login

OMB proposal to sideline peer review sparks widespread opposition
Nearly 500,000 public comments flood in—here are some highlights

Is psilocybin heading to a cancer clinic near you?
Reversing Nixon-era taboo, Trump orders FDA to fast-track psychedelics and ARPA-H to fund research